Pattern of relapse after first line treatment of advanced stage germ-cell tumors

European Urology

Volumn 48, Issue 6, 2005, Pages 957-964

  Flechon A ^a   Culine, S ^b   Theodore C ^c   Droz, J P ^a  

^a CENTRE LÉON BÉRARD   (France)

^b CENTRE VAL D AURELLE   (France)

^c INSTITUT GUSTAVE ROUSSY   (France)

Author keywords

Chemotherapy; Germ cell tumors; Surgery; Surveillance

Indexed keywords

CISPLATIN; ETOPOSIDE; IFOSFAMIDE; VINBLASTINE SULFATE;

ADVANCED CANCER; ANALYTIC METHOD; ARTICLE; BLOOD ANALYSIS; BONE METASTASIS; CANCER RELAPSE; CONTROLLED STUDY; FOLLOW UP; GERM CELL TUMOR; HUMAN; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; TERATOMA;

EID: 27844554503     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2005.06.018     Document Type: Article

References (23)

1. International germ cell consensus classification: a prognostic factor-based staging system for metastatic germ cell cancers. International Germ Cell Collaborative Group. J Clin Oncol 1997;15(2):594-603.
2. H.J. Schmoll, R. Souchon, S. Krege European Germ Cell Cancer Consensus Group European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG) Ann Oncol 15 9 2004 1377 1399
3. P.J. Loehrer Sr., R. Gonin, and C.R. Nichols Vinblastine plus ifosfamide plus cisplatin as initial salvage therapy in recurrent germ cell tumor J Clin Oncol 16 7 1998 2500 2504
4. R.J. Motzer, J. Sheinfeld, and M. Mazumdar Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer J Clin Oncol 18 2000 2413 2418
5. Non-seminomatous germ-cell tumors, in: Hamdy FC, Basler JW, Neal DE, Catalona WJ, editors. Management of urologic malignancies. London, Churchill Livingstone, First publish 2002. chap. 38, p. 450.
6. A. Gerl, C. Clemm, and N. Schmeller Prognosis after salvage treatment for unselected male patients with germ cell tumours Br J Cancer 72 4 1995 1026 1032
7. S.D. Fossa, S.P. Stenning, and A. Gerl Prognostic factors in patients progressing after cisplatin-based chemotherapy for malignant non-seminomatous germ cell tumours Br J Cancer 80 9 1999 1392 1399
8. R.J. Motzer, N.L. Geller, and C.C. Tan Salvage chemotherapy for patients with germ cell tumors. The Memorial Sloan-Kettering Cancer Center experience (1979-1989) Cancer 67 5 1991 1305 1310
9. L.H. Einhorn, S.D. Williams, and P.J. Loehrer Evaluation of optimal duration of chemotherapy in favorable-prognosis disseminated germ cell tumors: a Southeastern Cancer Study Group protocol J Clin Oncol 7 3 1989 387 391
10. H. Xiao, M. Mazumdar, and D.F. Bajorin Long-term follow-up of patients with good-risk germ cell tumors treated with etoposide and cisplatin J Clin Oncol 15 7 1997 2553 2558
11. R. de Wit, J.T. Roberts, and P.M. Wilkinson Equivalence of three or four cycles of bleomycin, etoposide, and cisplatin chemotherapy and of a 3- or 5-day schedule in good-prognosis germ cell cancer: a randomized study of the European Organization for Research and Treatment of Cancer Genitourinary Tract Cancer Cooperative Group and the Medical Research Council J Clin Oncol 19 6 2001 1629 1640
12. C.R. Nichols, S.D. Williams, and P.J. Loehrer Randomized study of cisplatin dose intensity in poor-risk germ cell tumors: a Southeastern Cancer Study Group and Southwest Oncology Group protocol J Clin Oncol 9 7 1991 1163 1172
13. S.B. Kaye, G.M. Mead, and S. Fossa Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study J Clin Oncol 16 2 1998 692 701
14. B.J. Roth, A. Greist, and P.S. Kubilis Cisplatin-based combination chemotherapy for disseminated germ cell tumors: long-term follow-up J Clin Oncol 6 8 1988 1239 1247
15. K. Fizazi, S. Tjulandin, and R. Salvioni Viable malignant cells after primary chemotherapy for disseminated nonseminomatous germ cell tumors: prognostic factors and role of postsurgery chemotherapy - results from an international study group J Clin Oncol 19 10 2001 2647 2657
16. A. Flechon, E. Tavernier, P. Meeus, M. Rivoire, and J.-P. Droz Study of the conformity of post-chemotherapy retroperitoneal lymph-node dissection (RPLND) to standard recommendations in patients with testicular (T) and primary retroperitoneal (PR) non-seminomatous germ-cell tumor (NSGCT): Impact on outcome Proc Am Soc Clin Oncol 22 14S 2004 4584
17. G.C. Toner, D.M. Panicek, and R.T. Heelan Adjunctive surgery after chemotherapy for nonseminomatous germ cell tumors: recommendations for patient selection J Clin Oncol 8 10 1990 1683 1694
18. C. Kollmannsberger, K. Oechsle, and B.M. Dohmen Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography with conventional assessment by computed tomography scans and serum tumor markers for the evaluation of residual masses in patients with nonseminomatous germ cell carcinoma Cancer 94 9 2002 2353 2362
19. A. Becherer, M. De Santis, and G. Karanikas FDG PET is superior to CT in the prediction of viable tumour in post-chemotherapy seminoma residuals Eur J Radiol 54 2 2005 284 288
20. C.J. Logothetis, M.L. Samuels, and A. Trindade The growing teratoma syndrome Cancer 50 8 1982 1629 1635
21. G.M. Jeffery, J.M. Theaker, and A.H. Lee The growing teratoma syndrome Br J Urol 67 2 1991 195 202
22. F. Andre, K. Fizazi, and S. Culine The growing teratoma syndrome: results of therapy and long-term follow-up of 33 patients Eur J Cancer 36 11 2000 1389 1394
23. S.D. Fossa, C. Bokemeyer, and A. Gerl Treatment outcome of patients with brain metastases from malignant germ cell tumors Cancer 85 4 1999 988 997